Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Reuters

Jul 31

<a href="https://laohu8.com/S/VIR">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2555838315"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555838315\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555838315?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-31 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555838315","market":"us","top_or_hot":-1,"title":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-31 20:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/VIR\">Vir Biotechnology</a> Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta <a href=\"https://laohu8.com/S/CHD\">$(CHD)$</a>. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus <a href=\"https://laohu8.com/S/HDV\">$(HDV)$</a> RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250731:nNDLtr9Rl:1","article_id":"2555838315","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555838315","pubTimestamp":1753963543,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta . The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus  RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","VIR":"Vir Biotechnology, Inc.","BK4568":"美国抗疫概念","BK4585":"ETF&股票定投概念","BK4535":"淡马锡持仓"},"translate_title":"Vir Biotechnology启动慢性δ型肝炎治疗3期ECLIPSE 2试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VIR":0.9},"content_text":"Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment\n    \n\n        Vir Biotechnology Inc. has announced the initiation of the ECLIPSE 2 Phase 3 clinical trial, part of its global ECLIPSE registrational program for chronic hepatitis delta $(CHD)$. The trial aims to evaluate the efficacy of combining tobevibart and elebsiran against continued bulevirtide monotherapy in patients with CHD who have not achieved undetectable levels of hepatitis delta virus $(HDV)$ RNA despite ongoing treatment with bulevirtide. ECLIPSE 2 is one of three trials in the program, designed to provide the necessary efficacy and safety data for potential submission to global regulatory agencies. This development follows compelling results from the Phase 2 SOLSTICE clinical trial, which demonstrated the potential of the investigational combination to reduce HDV to undetectable levels. The outcomes of ECLIPSE 2 will be presented in the future, pending the completion of the trial.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vir Biotechnology Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250731294819) on July 31, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}